Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Oxford Nanopore Technologies Plc | ONT | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.10 | -0.08% | 122.30 | 14:41:46 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 124.50 | 120.80 | 124.50 | 122.40 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 08/10/2024 07:06 by bamboo2 8 October 2024Oxford Nanopore Technologies plc Notification of intention to transfer listing category Oxford Nanopore Technologies plc ("Oxford Nanopore" or the "Company"), the company delivering a new generation of nanopore-based molecular sensing technology, today announces that it is proposing to transfer the listing category of its ordinary shares (the "Ordinary Shares") from the equity shares (transition) ("Transition") category to the equity shares (commercial companies) ("ESCC") category on the official list ("Official List") of the Financial Conduct Authority ("FCA") under Rule 21.5 of the UK Listing Rules ("UKLR") as modified by Transitional Provision 2 (the "Transfer"). The provision of a minimum of 20 business days' notice (which period commenced by way of today's announcement) is required to effect the Transfer. It is anticipated that the Transfer will take effect at 8:00 a.m. GMT on 6 November 2024. No shareholder approval is required in connection with the Transfer. This announcement is being made in accordance with UKLR 21.5.7. Dr. Gordon Sanghera, Chief of Executive Officer of Oxford Nanopore, commented: "We are proud of all we have achieved since our IPO in 2021, including significantly growing our revenues, customer base and impact in the scientific community. Today we are more excited than ever about the opportunities for our unique platform, that provides richer, multi-omic data, faster and more accessibly and affordably. As we look ahead, now is the right time for Oxford Nanopore to transfer to the ESCC segment. We believe it will provide exposure to a wider investor base and eligibility for FTSE index inclusion, enhancing the liquidity of our shares, for the benefit of our shareholders" |
Posted at 01/10/2024 06:07 by bamboo2 Novo NED joins board.1 October 2024 Oxford Nanopore Technologies plc Dr Daniel Mahony appointed as Non-Executive Director Oxford Nanopore Technologies plc (LSE: ONT) (''Oxford Nanopore'' or ''the Group''), the company delivering a new generation of nanopore-based molecular sensing technology, is pleased to announce that Dr Daniel Mahony will be joining the Group as a Non-Executive Director with effect from 1 October 2024. Daniel brings extensive sector experience to help accelerate Oxford Nanopore's commercial traction, with more than 25 years as a global healthcare investor specialising in biotechnology, medical technology and healthcare services. As Senior Partner in Growth Investments at Novo Holdings, Daniel will serve as a critical sounding board to the Group as it continues to advance its technology platform to address a significant commercial opportunity in biopharmaceuticals. In addition, he currently chairs the UK BioIndustry Association and is a Non-Executive Director of the Wellcome Sanger Institute. Prior to joining Novo Holdings, Daniel co-founded the healthcare business unit at Polar Capital in London, growing it to more than $4 billion in assets under management. He was formerly a Senior Research Analyst at Morgan Stanley in London, an Analyst at ING Barings Furman Selz in New York, and completed his postdoctoral work at DNAX Research Institute in Palo Alto. Dr Guy Harmelin, a non-executive director of the Group, who has served on the Board since 2020, has informed the Board of his intention to step down from the Board with effect from today. Dr Guy Harmelin, is stepping down to focus on various other Directorship responsibilities. Duncan Tatton-Brown, Chair of Oxford Nanopore, said: "We are extremely pleased to welcome Daniel to the board as Non-Executive Director of Oxford Nanopore. Daniel's deep knowledge of the biopharma sector, combined with his understanding of Oxford Nanopore's opportunity to drive value across the biopharma development pipeline, position him as an ideal source of expertise to support the company's commercial expansion into this space. I would like to thank Guy, our outgoing non-executive director for his outstanding support overall and contribution in helping the Group transition from a private to a public company during his tenure." Dr Daniel Mahony, incoming Non-Executive Director of Oxford Nanopore, said: "This is an exciting time for Oxford Nanopore with its expanding opportunity in biopharma, where rapid sequencing, richer data and a streamlined platform can support discovery and delivery of new biopharmaceuticals. I look forward to bringing my industry expertise to bear as Oxford Nanopore executes against its exciting growth plans in this sector." Dr Gordon Sanghera, Chief Executive Officer of Oxford Nanopore, said: "Daniel brings substantial strategic experience to support Oxford Nanopore's commercial growth in the life sciences and specifically the biopharma market. His perspectives will be invaluable as we continue to expand the use of our technology to address the needs of this industry, and I look forward to working with Daniel as we enter this next phase. I also would like to thank Guy, our outgoing non-executive director, for his insight and guidance during his tenure on the board. We appreciate his significant contribution and wish him well in his next chapter." Novo Holdings is a shareholder in Oxford Nanopore and led the recent £80 million equity placing. The decision to appoint Dr Mahony to the Board of Oxford Nanopore reflects his considerable industry expertise and the value he brings to the Board. |
Posted at 19/9/2024 10:50 by brucie5 It's been one of those remarkable opportunities to pick up a story that is clearly very much a reality, though not profit making, at, or near the bottom of an epic chart decline. Ample funding in place for next couple of years and with strategic investors well on board. Analogous to OXB earlier in the year; and I strongly believe, CWR in due course; though there needs to be something to provoke momentum, which is clearly evident here. Let's talk further about where it might go, once the share price has returned to the 2.30 area, where bM thought they were picking up a bargain almost one year ago... Pull out the three year chart and you can see we are still at the foothills. |
Posted at 08/9/2024 16:18 by bamboo2 Afaik, Oracle aka Ellison aka Delphi have been reducing their holding recently.Started with 35,294,117 [4.44%], recently reduced to 28,265,044 [3.004100%], allowing for dilution. Unfortunately they are following the pattern that was established here shortly after the floatation. One significant holder after another changing their minds about the co. Given that these are supposed to be professional investors, it's odd that they didn't choose to sell higher up. ================== Since the co became awash with cash, there's been some good work going on in the tech dept over the past few years, and after the new ASIC sees the light of day, I am anticipating some announcement on solid state nanopores. |
Posted at 05/9/2024 16:14 by brucie5 Final buys coming through at 142; and a large UT at 141.3 for 644k shares. Before that, a bizarre series of buys of 6 shares each!?I'm no market expert but the line seems to have been held today. I would imagine some degree of reluctance among retail investors who still don't trust the level. Give it a few more days, maybe. |
Posted at 05/9/2024 06:03 by bamboo2 5 September 2024Oxford Nanopore Technologies plc Oxford Nanopore to present at upcoming investor conferences Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore"), the company delivering a new generation of nanopore-based molecular sensing technology, will be presenting at the following investor conferences in September. · Goldman Sachs 21st Annual Medtech and Healthcare Services Conference on Thursday, 5 September at 9:00am BST in London, UK · BofA Securities Global Healthcare Conference 2024 on Wednesday, 18 September at 1:20pm BST in London, UK · Bernstein's 21st Pan European Annual Strategic Decisions Conference on Wednesday, 25 September at 9:00am BST in London, UK Live webcasts of the events can be accessed at the company's investor relations page at: Webcast replays will be available for at least 30 days following the events via the same link. |
Posted at 06/8/2024 10:54 by p1nkfish Good point steeple. I'm suspicious there are moves in the UK market normal plebs can't understand as not sitting at the table being consulted. Big investors are likely to be consulted and its not past any of them not to front run decisions. |
Posted at 01/8/2024 06:38 by bamboo2 Oxford Nanopore attracts investment from Novo Holdings and completes Equity Issue of £80 millionOxford Nanopore announces the successful completion of the bookbuilding process for the placing of new ordinary shares of £0.0001 each in the capital of the Company ("New Ordinary Shares") announced yesterday (the "Placing"). In light of the strong demand from investors, with the transaction multiple times oversubscribed, the Board has decided to increase the size of the Equity Issue from approximately £75 million to £80 million. A total of 25,000,000 New Ordinary Shares (the "Placing Shares") have been placed by Citigroup Global Markets Limited ("Citi"), J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove) ("J.P. Morgan Cazenove") and Joh. Berenberg, Gossler & Co. KG ("Berenberg" and, together with Citi and J.P. Morgan Cazenove, the "Joint Bookrunners") at a price of 120 pence per Placing Share (the "Placing Price") raising gross proceeds of approximately £30 million. As a result of the successful placing, the subscription by Novo Holdings A/S ("Novo Holdings") has been reduced from £60 million such that it will subscribe for 41,666,667 New Ordinary Shares (the "Subscription Shares") at the Placing Price, raising gross proceeds of approximately £50 million. Novo Holdings currently intends, subject, inter alia, to availability and price, to add over time to their initial primary investment through further market purchases of up to £10 million. Therefore, the Placing and Subscription (together, the "Equity Issue") will raise total gross proceeds of approximately £80 million. Dr. Gordon Sanghera, CEO, Oxford Nanopore said: "We are delighted to welcome this new, strategic investment from Novo Holdings, alongside continuing support from our existing investors. Over recent years, we have further iterated our technology platform and commercial infrastructure and are poised to gain further traction in broad sectors including scientific research, clinical and applied industrial markets. The investment from Novo Holdings reflects our ambition in the biopharmaceutical sector. Our technology platform is uniquely suited to address the needs of this industry where information-rich, rapid and simplified sequencing are critical to developing and delivering biopharmaceuticals faster and with less complexity. We look forward to their support." Together, the Placing Shares and Subscription Shares ("New Ordinary Shares") being issued represent approximately 8 per cent. of the issued ordinary share capital of Oxford Nanopore prior to the Equity Issue. The Placing Price of 120 pence represents a discount of approximately 0.7 per cent. to the closing share price of 120.80 pence on 31 July 2024. As per the new U.K. listing regime, applications have been made for the New Ordinary Shares to be admitted to the "transition" listing segment of the Official List (the "Official List") of the Financial Conduct Authority (the "FCA") and to be admitted to trading on the main market for listed securities of the London Stock Exchange plc (the "London Stock Exchange") (together, "Admission"). Settlement of the New Ordinary Shares and Admission are expected to take place on or around 8.00 a.m. on 5 August 2024. The Placing is conditional upon, amongst other things, Admission becoming effective and upon the placing agreement between the Joint Bookrunners and the Company not being terminated in accordance with its terms. The New Ordinary Shares, when issued, will be fully paid and will rank pari passu in all respects with each other and with the existing Ordinary Shares, including, without limitation, the right to receive all dividends and other distributions declared, made or paid after the date of issue. Following Admission, the total number of Ordinary Shares in issue in Oxford Nanopore will be 940,896,164. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in Oxford Nanopore will be 940,896,164 following Admission, and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Oxford Nanopore under the FCA's Disclosure Guidance and Transparency Rules. Citi, J.P. Morgan Cazenove and Berenberg acted as Joint Global Coordinators, Joint Bookrunners and Joint Corporate Brokers in respect of the Placing. About Novo Holdings Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people's health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation. Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S (Novozymes A/S) and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seed, Venture, Growth, Asia, Planetary Health and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development. As of year-end 2023, Novo Holdings had total assets of €149 billion. www.novoholdings.dk |
Posted at 31/7/2024 16:29 by palisz Oxford Nanopore attracts investment from Novo Holdings and announces proposed placing of new ordinary sharesThe Equity Issue comprises the issue of new ordinary shares of £0.0001 each in the capital of the Company ("New Ordinary Shares"), at an issue price of 120 pence per New Ordinary Share through: a strategic investment from Novo Holdings A/S ("Novo Holdings"), a world leading life sciences investor, of up to £60 million, pursuant to which Novo Holdings has committed to subscribe for New Ordinary Shares (the "Subscription Shares") at the Placing Price and.. a placing to institutional investors by the issue of New Ordinary Shares (the "Placing Shares") at the Placing Price (the "Placing"). |
Posted at 21/10/2023 06:26 by bamboo2 Oxford Nanopore Technologies Outlines Plans to Expand Presence in Clinical, Applied MarketsOct 20, 2023 H Zhang Premium Use link for complete article NEW YORK – Hosting its inaugural Capital Markets Day event in London on Thursday, Oxford Nanopore Technologies delineated its ambition and strategies to further penetrate the clinical and applied markets with its nanopore sequencers. The company set the stage for the webcast event, which was open to institutional investors and financial analysts, by announcing its newly minted collaboration with Mayo Clinic and a £70 million ($84.6 million) strategic investment deal from French in vitro diagnostics firm BioMérieux. "As clinical lab networks globally are expanding, we see this as a key opportunity for nanopore sequencing to enter clinical and diagnostics markets," Emma Stanton, Oxford Nanopore's Clinical VP, told investors. According to Stanton, the company's collaboration with Mayo will first focus on breast cancer, specifically for the detection of BRAC1 and BRCA2 mutations. The collaborators are also interested in working on sequencing assays for rare cancers and infectious diseases. For its partnership with BioMérieux, Stanton said the companies are working together to roll out a nanopore sequencing-based test for the rapid identification and characterization of drug-resistant tuberculosis. Besides that, she said they are working to validate nanopore data on BioMérieux's EPISeq software, which is used for hospital infectious disease surveillance and outbreak monitoring. Furthermore, Stanton said Oxford Nanopore and BioMérieux will co-develop an IVD reflex test for clinical pathogen identification using targeted amplicon sequencing. "We always look for things that are faster, give more actionable information, and are easier to use," said Mark Miller, executive vice president and chief medical officer of BioMérieux. "It's natural for us to then take the next step and want to collaborate and develop products [with Oxford Nanopore] that really start impacting patients and infectious diseases." When asked by investors whether nanopore sequencing would undermine the company's existing BioFire multiplex PCR platform for infectious disease testing, Miller asserted that the former is "not cannibalistic at all" but rather "very complimentary and additive" to the company's product portfolio. "I don't think that with multiplex PCR you are going to achieve the degree of confidence in tuberculosis and tuberculosis [antibiotic] resistance that you will with nanopore sequencing," he said. "Nanopore sequencing gives you a vast number of genes and mutations that are relevant for antibiotic resistance on the most commonly used drugs, which we cannot obtain right now with multiplex PCR, and we are not going for." Overall, Stanton said the newly announced partnerships fit into the four pillars of Oxford Nanopore''s clinical strategy. These include collaborating with leading clinical institutions, deploying a dedicated clinical commercial sales team, developing end-to-end diagnostic solutions, and forging commercial partnerships with diagnostics firms that have established expertise, commercial presence, and market access. Additionally, she pointed out that the top three clinical and diagnostic market segments for Oxford Nanopore are oncology, human genetics diseases, and infectious disease. Still, all of Oxford Nanopore's products currently are developed for research use only, although labs can leverage them to develop and validate their own laboratory-developed tests (LDTs), Stanton said. To that end, she noted that the company will eventually need to have a "more prescribed and documented approach" for its products to achieve regulatory compliance such as IVDR marking and US Food and Drug Administration approval. However, the company declined to comment on which product it plans to seek regulatory approval for first, and it did not disclose a concrete timeline. During the event, Louisa Ludbrook, Oxford Nanopore's VP of commercial market development, accentuated the company's so-called Q-Line sequencing portfolio, which includes ISO9001-certified, locked-down versions of instruments and sample prep reagents to help industrial or clinical customers who desire to implement long-term and stabilized nanopore sequencing workflows. She also highlighted the company's ongoing partnerships in industrial markets. These include a collaboration with PathoQuest, a next-generation sequencing-based biosafety testing firm, to commercialize tests for biomanufacturing quality control — both good manufacturing practices (GMP)-validated and non-GMP. According to her, the non-GMP assay is now available while the GMP-validated test is expected to launch in early 2024. In addition, she said the company is working with the Base facility within the University of Queensland in Australia for nanopore sequencing-based mRNA vaccine quality control testing. "Together we'll develop a rapid, comprehensive direct RNA sequencing test suitable for industry use, and we're currently in discussions regarding commercial evaluation of this test," Ludbrook told investors. As Oxford Nanopore moves into the clinical diagnostic and applied markets, the company is also focusing heavily on partnerships and collaborations to share resources, build new nanopore sequencing-based products, and equally reap the benefits, said Oxford Nanopore's senior VP of corporate and business development John Schoellerman. It remains to be seen how much penetration into the clinical market the company can achieve in the near term, especially given the increasingly competitive next-generation sequencing landscape. In 2021, the company established a subsidiary called Oxford Nanopore Diagnostics to help develop validated clinical diagnostic tools harnessing nanopore sequencing. However, the company has largely remained quiet since its inception, and Oxford Nanopore's 2022 annual report listed the subsidiary's principal activity as "dormant." Oxford Nanopore did not respond to a request to comment on the future role Oxford Nanopore Diagnostics will play in helping the company go after clinical markets. When asked about what percentage of the company's current revenues are directly related to the clinical diagnostic segments during the Q&A portion of the event, CEO Gordon Sanghera said, "If we define clinical as not discovery and translational, then I would say very little." "It's too early to figure out what that looks like, as we're at the beginning in the foothills of these tests," he added. JP Morgan analyst James Gordon, who attended the event, wrote in a note to investors that it feels like the company "has turned a corner" with technological development now mostly complete and commercialization stepping up. "Though we believe there is still further detail to be fleshed out on this expansion, we see the company as well placed to deliver very strong topline growth for many years and we also came away with increased confidence in the company's ability to also deliver on the plans to reach profitability," Gordon noted. Commenting on competition in the nanopore sequencing space, Sanghera said while there is a rumor that Roche might launch a platform imminently, "we have not seen anything yet." Still, he said the company's "highly differentiated platform has significant first-mover advantage," and its "evergreen" IP portfolio has managed to "defend our position and block entrants." In that regard, he also pointed to upcoming product launches, including TurBot, a benchtop device capable of "fully hands off" sample extraction, library prep, sequencing, and data analysis, as well as TraxIon, a hand-held device also capable of carrying out the end-to-end nanopore sequencing workflow. He also teased the audience with a so-called voltage chip that the company is developing, which will come with 10,000 to 100,000 channels and "ultimately lead to a one-hour, $10 genome." "Don't ask me when that's going to happen," Sanghera said. "It's three to five years out." |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
